Opinion
News Analysis
The Year Ahead
Business
and Finance
Who Pays for What?
Case Study: Brazil
Case Study: Regeneron
Case Study: NitroMed
People:
Edison Liu
People:
Steve Holtzman
People:
Corey Goodman
Future Trend
Science, Technology,
and Medicine
Policy, Society,
and Ethics
Reviews
Metrics
Common Sense
Editor's Letter




spacer

Business and Finance

Prescription prices and health care costs still shadow the life sciences industry. But for biotechnology companies, an open IPO window and lucrative licensing deals may mean rosy days ahead.

FEATURES

Who Pays for What?  By Kevin Kelleher
The cost of a drug depends on opaque negotiations and secret deals, not on patient demands.

 

CASE STUDIES

Brazil
Now that the country has cashed in on its GMO-free image, it could displace the United States as the world’s leading soybean exporter. But recent economic pressures have added transgenic seeds to the mix.

Regeneron Pharmaceuticals
This company recovered from critical condition with the help of a white knight and a successful rival.

NitroMed
Here’s how one of the few companies to go public last fall used its understanding of heart disease in African American populations to in-license a drug that had failed its earlier endpoints.

spacer
spacer spacer

PEOPLE

Edison Liu

Steve Holtzman

Corey Goodman

 

FUTURE TREND

Victor Fuchs

spacer